georgie18
2 weeks ago
CPIX...$2.33...Trying to Reverse here...🥳
georgie18
Member Level
Re: georgie18 post# 667357
Tuesday, December 10, 2024 8:16:14 AM
Post#
667359
of 668190
CPIX...$3.07...🥳...Off my $2.15 Alert...
georgie18
Member Level
Re: georgie18 post# 97
Tuesday, December 10, 2024 8:12:33 AM
Post#
102
of 102
CPIX...$2.71...🥳...Off my $2.15 Alert...
georgie18
Member Level
Re: georgie18 post# 667334
Monday, December 09, 2024 4:26:19 PM
Post#
667337
of 667357
CPIX...$2.27...🥳
georgie18
Member Level
Re: None
Monday, December 09, 2024 4:19:53 PM
Post#
96
of 96
CPIX...$2.15...🥳...NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a supplemental New Drug Application (sNDA) for its Acetadote® (N-acetylcysteine for injection) product. Acetadote is an intravenous (IV) formulation of N-acetylcysteine (NAC) indicated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen1.
georgie18
3 weeks ago
CPIX...$3.07...🥳...Off my $2.15 Alert...
georgie18
Member Level
Re: georgie18 post# 97
Tuesday, December 10, 2024 8:12:33 AM
Post#
102
of 102
CPIX...$2.71...🥳...Off my $2.15 Alert...
georgie18
Member Level
Re: georgie18 post# 667334
Monday, December 09, 2024 4:26:19 PM
Post#
667337
of 667357
CPIX...$2.27...🥳
georgie18
Member Level
Re: None
Monday, December 09, 2024 4:19:53 PM
Post#
96
of 96
CPIX...$2.15...🥳...NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a supplemental New Drug Application (sNDA) for its Acetadote® (N-acetylcysteine for injection) product. Acetadote is an intravenous (IV) formulation of N-acetylcysteine (NAC) indicated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen1.
georgie18
3 weeks ago
CPIX...$2.71...🥳...Off my $2.15 Alert...
georgie18
Member Level
Re: georgie18 post# 667334
Monday, December 09, 2024 4:26:19 PM
Post#
667337
of 667357
CPIX...$2.27...🥳
georgie18
Member Level
Re: None
Monday, December 09, 2024 4:19:53 PM
Post#
96
of 96
CPIX...$2.15...🥳...NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a supplemental New Drug Application (sNDA) for its Acetadote® (N-acetylcysteine for injection) product. Acetadote is an intravenous (IV) formulation of N-acetylcysteine (NAC) indicated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen1.
XenaLives
3 years ago
Historic short interest -
You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest
Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch
Settlement Date Short Interest Percent Change
Average Daily Share Volume Days to Cover
04/29/2022 82,394 (9.27) 22,137 3.72
04/14/2022 90,811 23.95 47,392 1.92
03/31/2022 73,266 (42.79) 65,105 1.13
03/15/2022 128,075 (14.39) 47,132 2.72
02/28/2022 149,597 (13.52) 21,166 7.07
02/15/2022 172,991 (28.49) 42,199 4.10
01/31/2022 241,922 (46.03) 165,710 1.46
01/14/2022 448,233 (25.38) 346,134 1.29
12/31/2021 600,696 (51.92) 628,412 1.00
12/15/2021 1,249,480 47717.83 7,280,845 1.00
11/30/2021 2,613 (34.49) 22,632,999 1.00
11/15/2021 3,989 (95.41) 102,287 1.00
10/29/2021 86,964 7.22 26,424 3.29
10/15/2021 81,107 (0.08) 29,832 2.72
09/30/2021 81,168 (24.11) 20,302 4.00
09/15/2021 106,956 21.94 26,331 4.06
08/31/2021 87,712 (2.23) 26,402 3.32
08/13/2021 89,714 4.18 20,032 4.48
07/30/2021 86,114 (3.20) 19,243 4.48
07/15/2021 88,957 (18.41) 31,149 2.86
06/30/2021 109,027 3.41 21,339 5.11
06/15/2021 105,427 2.04 37,914 2.78
05/28/2021 103,316 2.20 29,626 3.49
05/14/2021 101,096 0.78 27,897 3.62
04/30/2021 100,312 (6.00) 21,561 4.65
04/15/2021 106,716 5.36 30,033 3.55
03/31/2021 101,286 (4.91) 24,409 4.15
03/15/2021 106,515 3.11 56,041 1.90
02/26/2021 103,304 2.54 76,050 1.36
02/12/2021 100,744 2.07 75,289 1.34
XenaLives
3 years ago
profile pic
XenaLives
RE: None
Monday, February 14, 2022 2:39:28 PM
Post#
90
of 91
Historic short interest -
You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest
Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch
Settlement Date Short Interest Percent Change
Average Daily Share Volume Days to Cover
03/15/2022 128,075 (14.39) 47,132 2.72
02/28/2022 149,597 (13.52) 21,166 7.07
02/15/2022 172,991 (28.49) 42,199 4.10
01/31/2022 241,922 (46.03) 165,710 1.46
01/14/2022 448,233 (25.38) 346,134 1.29
12/31/2021 600,696 (51.92) 628,412 1.00
12/15/2021 1,249,480 47717.83 7,280,845 1.00
11/30/2021 2,613 (34.49) 22,632,999 1.00
11/15/2021 3,989 (95.41) 102,287 1.00
10/29/2021 86,964 7.22 26,424 3.29
10/15/2021 81,107 (0.08) 29,832 2.72
09/30/2021 81,168 (24.11) 20,302 4.00
09/15/2021 106,956 21.94 26,331 4.06
08/31/2021 87,712 (2.23) 26,402 3.32
08/13/2021 89,714 4.18 20,032 4.48
07/30/2021 86,114 (3.20) 19,243 4.48
07/15/2021 88,957 (18.41) 31,149 2.86
06/30/2021 109,027 3.41 21,339 5.11
06/15/2021 105,427 2.04 37,914 2.78
05/28/2021 103,316 2.20 29,626 3.49
05/14/2021 101,096 0.78 27,897 3.62
04/30/2021 100,312 (6.00) 21,561 4.65
04/15/2021 106,716 5.36 30,033 3.55
03/31/2021 101,286 (4.91) 24,409 4.15
03/15/2021 106,515 3.11 56,041 1.90
02/26/2021 103,304 2.54 76,050 1.36
02/12/2021 100,744 2.07 75,289 1.34
XenaLives
3 years ago
Historic short interest -
You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest
Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch
Settlement Date Short Interest Percent Change
Average Daily Share Volume Days to Cover
01/31/2022 241,922 (46.03) 165,710 1.46
01/14/2022 448,233 (25.38) 346,134 1.29
12/31/2021 600,696 (51.92) 628,412 1.00
12/15/2021 1,249,480 47717.83 7,280,845 1.00
11/30/2021 2,613 (34.49) 22,632,999 1.00
11/15/2021 3,989 (95.41) 102,287 1.00
10/29/2021 86,964 7.22 26,424 3.29
10/15/2021 81,107 (0.08) 29,832 2.72
09/30/2021 81,168 (24.11) 20,302 4.00
09/15/2021 106,956 21.94 26,331 4.06
08/31/2021 87,712 (2.23) 26,402 3.32
08/13/2021 89,714 4.18 20,032 4.48
07/30/2021 86,114 (3.20) 19,243 4.48
07/15/2021 88,957 (18.41) 31,149 2.86
06/30/2021 109,027 3.41 21,339 5.11
06/15/2021 105,427 2.04 37,914 2.78
05/28/2021 103,316 2.20 29,626 3.49
05/14/2021 101,096 0.78 27,897 3.62
04/30/2021 100,312 (6.00) 21,561 4.65
04/15/2021 106,716 5.36 30,033 3.55
03/31/2021 101,286 (4.91) 24,409 4.15
03/15/2021 106,515 3.11 56,041 1.90
02/26/2021 103,304 2.54 76,050 1.36
02/12/2021 100,744 2.07 75,289 1.34
XenaLives
3 years ago
Financials -
Page 9 of the PDF- operating at a loss
Page 13 of the PDF -
Restricted Share Grants and Incentive Stock Options
During the nine months ended September 30, 2021 and September 30, 2020, the Company issued 36,850 shares and 230,491 shares of restricted stock to employees and directors, respectively.
Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant. During the nine months ended September 30, 2021, the Company also issued 174,800 incentive stock options to employees that cliff-vest on the fourth anniversary of the date of grant, that are set to expire in March and May 2031. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.
Page 14 of the PDF:
(7) (8) COLLABORATIVE AGREEMENTS
Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is
primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the
collaborative payment received related to RediTrex, do not meet the criteria for accounting under ASC Topic 808, Collaborative Agreements. The agreements do not specifically designate each
party’s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.
Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed
consolidated statements of operations.
Our primary target markets are hospital acute care, gastroenterology and rheumatology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by small, targeted sales forces. We promote our approved products through our hospital and field sales forces in the United States and are establishing a network of international partners to register and provide our medicines to patients in their countries.
Our portfolio of FDA approved brands include:
• Acetadote (acetylcysteine) Injection, for the treatment of acetaminophen poisoning;
• Caldolor (ibuprofen) Injection, for the treatment of pain and fever;
• Kristalose (lactulose) for Oral Solution, a prescription laxative, for the treatment of constipation;
• Omeclamox -Pak, (omeprazole, clarithromycin, and amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease;
• RediTrex (methotrexate) Injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis;
• Vaprisol (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
• Vibativ (telavancin) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
In addition to these commercial brands, we have Phase II clinical programs underway evaluating our ifetroban product candidates being used by patients with cardiomyopathy associated with Duchenne Muscular Dystrophy (“DMD”), a degenerative disease, Systemic Sclerosis (“SSc”), a deadly autoimmune condition, and Aspirin-Exacerbated Respiratory Disease (“AERD”), a severe form of asthma.
Cumberland has built core competencies in both the development and commercialization of pharmaceutical products. We have established the capabilities needed to acquire, develop and commercialize branded pharmaceuticals in the U.S. and believe we can leverage this existing infrastructure to support our expected growth. Our management team consists of pharmaceutical industry veterans experienced in business development, product development, regulatory, manufacturing, sales, marketing and finance.
Our business development team identifies, evaluates, and negotiates product acquisition, licensing and co-promotion agreements. Our product development team creates proprietary product formulations, manages our clinical studies, prepares all regulatory submissions and staffs our medical call center. Our quality and manufacturing professionals oversee the manufacturing, release and shipment of our products. Our marketing and sales team is responsible for our commercial activities, and we work closely with our distribution partners to ensure availability and delivery of our products.
https://investor.cumberlandpharma.com/static-files/06fffd58-af5a-4242-ba79-8a51e71a7e0d
XenaLives
3 years ago
Long term 15 day chart -
Again, disproportionate volume recently.
2010 options program instituted:
https://investor.cumberlandpharma.com/node/8981/html
Issues with employee redemption during IPO:
Cumberland Pharma employee sues over stock options
ERIN LAWLEY JUL 8, 2010
Facebook
Twitter
Email
Print
Save
A Cumberland Pharmaceuticals employee has filed suit against the company, alleging the firm violated his stock option rights, preventing him from maximizing his profits.
The complaint, filed in Nashville's U.S. District Court late last month and available at this link, says Paul Boersig, a hospital sales representative, entered into a pair of incentive stock option agreements in 2003 and 2005. It alleges the company honored only the options from the 2005 plan and that, when Boersig wanted to exercise those options, it presented a series of hurdles that effectively limited the amount of money he could recover from his trades.
The latter point specifically relates to Cumberland’s $85 million initial public offering in August of 2009. The company notified employees that they could not trade their options during a 180-day "lockup period" following the IPO, but that they must wait for a “trading window” following the company’s release of its 2009 year-end financial results.
According to Boersig’s complaint, however, the company provided none of the promised communication on how employees could go about exercising their options once the trading window opened and "twice refused" Boersig the opportunity to purchase shares after he had acknowledged "that it was his intention to sell the shares during the trading window."
Though Boersig did succeed in selling the bulk of his shares, the "deliberately cumbersome" process kept him from exercising all his options. In addition, he later discovered the company permitted its senior vice president and corporate secretary to exercise options prior to the conclusion of the lockup period, at a higher per-share price.
"Cumberland engaged in a course of conduct designed to thwart Boersig's rights to trade his options pursuant to the plan, and for him to recognize as many losses as possible, contrary to its fiduciary obligations to him," the complaint reads.
Boersig is seeking unspecified damages related to violation of the Employee Retirement Income Security Act, breach of contract, breach of fiduciary duty and breach of duty of good faith and fair dealing.
Anne Martin of Bone McAllester Norton filed suit on behalf of Boersig.
In a statement emailed to NashvillePost.com, Cumberland Pharmaceuticals said it "works hard to balance the interests of patients, shareholders and employees" to provide them value. "Compliance with all federal equity and other regulations is of utmost importance at Cumberland, and the company believes it has operated and continues to operate with strict adherence to such regulations," it said.
https://www.nashvillepost.com/business/health_care/cumberland-pharma-employee-sues-over-stock-options/article_3c7305b6-4d9d-51a1-94dd-47d07e7a9c36.html
XenaLives
3 years ago
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. The Company develops, acquires, and commercializes brands for the hospital acute care, gastroenterology and rheumatology market segments. The Company's portfolio of FDA-approved brands includes:
-Acetadote® (acetylcysteine) Injection, for the treatment of acetaminophen poisoning;
-Caldolor® (ibuprofen) Injection, for the treatment of pain and fever;
-Vaprisol® (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;
-Vibativ® (telavancin) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections;
-Kristalose® (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;
RediTrex® (methotrexate) Injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis; and
-Omeclamox®-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease.
For more information on Cumberland's approved products, including full prescribing information, please visit the individual product websites, links to which can be found on the Company's website www.cumberlandpharma.com.
The Company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidates in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy ("DMD"), Systemic Sclerosis ("SSc"), and Aspirin-Exacerbated Respiratory Disease ("AERD").
https://cumberlandpharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/caldolorr-now-fda-approved-pre-operative-administration
News
Market Data
Register for real-time alerts, custom portfolio, and market movers
tw0122
3 weeks ago
TrendTrade2016
3 weeks ago
glenn1919
3 weeks ago
Minddoc7
3 years ago
HokieHead
3 years ago
TheFinalCD
3 years ago
PStockPickz
3 years ago
